HCPCS Q5119

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (CMS descriptor)

Drugs Drug code

39
54th percentile among 6,116 codes billed · 2020
$4.6M
83rd percentile among 6,116 codes billed · 2020
80K
84th percentile among 6,116 codes billed · 2020
1,760
97th percentile among 6,116 codes billed · 2020
3,772
96th percentile among 6,116 codes billed · 2020

Trend

Medicare payment on the code

$0$20M$40M2020: $4.6M paid20202021: $48M paid20212022: $37M paid20222023: $16M paid20232024: $5.7M paid2024$5.7M$0$20M$40M2020: $4.6M paid20202021: $48M paid20212022: $37M paid20222023: $16M paid20232024: $5.7M paid2024$5.7M$0$20M$40M2020: $4.6M paid20202021: $48M paid20212022: $37M paid20222023: $16M paid20232024: $5.7M paid2024$5.7M$0$20M$40M2020: $4.6M paid20202021: $48M paid20212022: $37M paid20222023: $16M paid20232024: $5.7M paid2024$5.7M

Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.

Billers

02004002020: 39 providers20202021: 364 providers20212022: 415 providers20222023: 335 providers20232024: 133 providers202413302004002020: 39 providers20202021: 364 providers20212022: 415 providers20222023: 335 providers20232024: 133 providers202413302004002020: 39 providers20202021: 364 providers20212022: 415 providers20222023: 335 providers20232024: 133 providers202413302004002020: 39 providers20202021: 364 providers20212022: 415 providers20222023: 335 providers20232024: 133 providers2024133

Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.

Trend by year: table5 years
observed calculated calculated calculated calculated calculated reported
2024133$5,663,100-65%355,1432,1305,4720.00
2023335$16,350,137-56% (2023 changed hospital and observation visit codes)736,4031,7904,2620.00
2022415$36,822,628-23%988,9082,0104,8180.00
2021364$47,846,717– (Not compared: 2021 changed office visit values)951,1152,3404,9500.00
202039$4,591,121first year in data79,9951,7603,772

Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.

By state

No state has a reportable line for Q5119 in 2020.

Top metro areas

No metro area has a reportable line for Q5119 in 2020.

Specialties billing Q5119 nationally

Hematology-Oncology accounts for 77% of payment for Q5119 nationally in 2020, across 1 specialties on claims.

observed calculated calculated calculated calculated calculated
Hematology-Oncology2872%$3,521,58677%61,1682,185

Not listed: 2 specialties with fewer than 11 billers (small cells).

Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Provider-level lines (fewer than 11 beneficiaries suppressed by CMS); specialty is the provider type on claims. Data year 2020.

Top billers of Q5119 nationally

Named top billers are a Pro figure, and Pro is not available to buy, so this list is not shown to any account. The counts and totals by state, metro area and specialty on this page are free.

Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed · Limitations